Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Depreciation & Amortization (CF): 2015-2025

Historic Depreciation & Amortization (CF) for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to $2.4 million.

  • Intellia Therapeutics' Depreciation & Amortization (CF) fell 7.69% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year decrease of 2.17%. This contributed to the annual value of $10.3 million for FY2024, which is 14.44% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Depreciation & Amortization (CF) of $2.4 million as of Q3 2025, which was down 4.00% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Depreciation & Amortization (CF) registered a high of $2.6 million during Q2 2024, and its lowest value of $1.6 million during Q1 2021.
  • Its 3-year average for Depreciation & Amortization (CF) is $2.4 million, with a median of $2.5 million in 2025.
  • Per our database at Business Quant, Intellia Therapeutics' Depreciation & Amortization (CF) rose by 22.54% in 2024 and then fell by 7.69% in 2025.
  • Quarterly analysis of 5 years shows Intellia Therapeutics' Depreciation & Amortization (CF) stood at $1.9 million in 2021, then grew by 9.00% to $2.1 million in 2022, then climbed by 20.93% to $2.5 million in 2023, then climbed by 3.65% to $2.6 million in 2024, then declined by 7.69% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $2.5 million for Q2 2025, and $2.5 million during Q1 2025.